Gerbes A L, Møller S, Gülberg V, Henriksen J H
Department of Medicine II, Klinikum Grosshadern, University of Munich, Germany.
Hepatology. 1995 Mar;21(3):735-9.
Increased as well as decreased plasma concentrations of the endothelins, endogenous vasoactive peptides, have been reported in cirrhosis. This might be caused by alterations of hepatic or renal clearance or release. Therefore, the aim of the current study was to investigate the influence of splanchnic and renal passage and of liver function on plasma concentrations of endothelin-1 (ET-1) and endothelin-3 (ET-3) in patients with cirrhosis compared with controls. Eighteen patients with cirrhosis and 8 normotensive controls of similar age were investigated. Arterial and venous plasma samples were obtained simultaneously, and ET-1 and ET-3 concentrations were determined in extracted plasma by two separate radioimmunoassays. Arterial as well as hepatic and renal venous concentrations of ET-1 in cirrhosis (17.8 +/- 0.8 pg/mL, 19.1 +/- 0.9 pg/mL, and 16.8 +/- 0.8 pg/mL) were significantly (P < .001) higher than in controls (9.2 +/- 1.7 pg/mL, 9.0 +/- 2.0 pg/mL, and 8.4 +/- 1.9 pg/mL, respectively). The same held true for the corresponding ET-3 plasma concentrations in cirrhosis (19.3 +/- 1.6 pg/mL, 20.5 +/- 1.5 pg/mL, and 18.4 +/- 1.5 pg/mL, respectively) compared with controls (11.1 +/- 1.8 pg/mL, 11.3 +/- 1.5 pg/mL, and 10.1 +/- 1.7 pg/mL, respectively; P < .01). There was a significant (P < .05) renal net extraction of ET-1 and ET-3 in cirrhosis. In contrast, a significant (P < .05) net release of ET-1 and ET-3 (2.40 +/- 0.80 ng/min and 1.75 +/- 1.16 ng/min) during splanchnic passage was observed in cirrhosis, but not in controls (-0.24 +/- 0.51 ng/min, and -0.46 +/- 0.64 ng/min).(ABSTRACT TRUNCATED AT 250 WORDS)
据报道,肝硬化患者体内内皮素(一种内源性血管活性肽)的血浆浓度既有升高的情况,也有降低的情况。这可能是由于肝脏或肾脏清除或释放功能的改变所致。因此,本研究的目的是探讨与对照组相比,肝硬化患者内脏和肾脏通路以及肝功能对血浆内皮素 -1(ET -1)和内皮素 -3(ET -3)浓度的影响。研究了18例肝硬化患者和8例年龄相仿的血压正常的对照组。同时采集动脉和静脉血浆样本,并通过两种独立的放射免疫分析法测定提取血浆中的ET -1和ET -3浓度。肝硬化患者动脉、肝静脉和肾静脉中ET -1的浓度(分别为17.8±0.8 pg/mL、19.1±0.9 pg/mL和16.8±0.8 pg/mL)显著高于对照组(分别为9.2±1.7 pg/mL、9.0±2.0 pg/mL和8.4±1.9 pg/mL;P <.001)。肝硬化患者相应的ET -3血浆浓度(分别为19.3±1.6 pg/mL、20.5±1.5 pg/mL和18.4±1.5 pg/mL)与对照组相比(分别为11.1±1.8 pg/mL、11.3±1.5 pg/mL和10.1±1.7 pg/mL;P <.01)也是如此。肝硬化患者对ET -1和ET -3有显著的肾脏净摄取(P <.05)。相比之下,肝硬化患者在内脏通路期间观察到ET -1和ET -3有显著的净释放(分别为2.40±0.80 ng/min和1.75±1.16 ng/min),而对照组未观察到(分别为 -0.24±0.51 ng/min和 -0.46±0.64 ng/min)。(摘要截断于250字)